Pfizer CEO granted phantom stock units

Q: What insider transaction did Pfizer (PFE) report for Albert Bourla on this Form 4?

Albert Bourla received a grant of 24.0000 Phantom Stock Units SSP tied to Pfizer common stock. These units are part of a deferred compensation arrangement and are reported as derivative securities acquired on July 31, 2026.

Q: What are the key terms of the Phantom Stock Units reported by Pfizer (PFE)?

Each Phantom Stock Unit represents one phantom share of Pfizer common stock and is settled in cash. The units were acquired under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan and may be moved into an alternative investment account at any time.

Q: How many phantom stock units does Albert Bourla hold after this Pfizer (PFE) Form 4 transaction?

After the reported grant, Albert Bourla holds a total of 786154.0000 Phantom Stock Units SSP. This total reflects all such units reported as directly owned following the July 31, 2026 award of 24.0000 additional units.

Q: Was the Pfizer (PFE) Form 4 transaction for Albert Bourla a purchase or a grant?

The transaction is reported as a grant/award acquisition of Phantom Stock Units, coded “A” for acquisition. It represents compensation awarded under a deferred compensation plan, not an open-market stock purchase or sale.

Q: How is the value of Albert Bourla’s Pfizer (PFE) Phantom Stock Units measured in this Form 4?

The reported reference price for the grant is $25.0100 per unit. Each unit corresponds to one phantom share of common stock, and the units are ultimately settled in cash following Bourla’s separation from service from Pfizer.

BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 08/03/2026 - 07:50 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

BOURLA ALBERT reported acquisition or exercise transactions in this Form 4 filing.

Pfizer Inc. Chairman & CEO Albert Bourla received a grant of 24.0000 Phantom Stock Units SSP on July 31, 2026 under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. Each unit represents one phantom share of common stock and is settled in cash after separation from service, increasing his reported phantom unit balance to 786154.0000.

Insider Trade Summary

Grant/Award: 24 shares

Grant/Award 1 txn

Insider BOURLA ALBERT

Role Chairman & CEO

Type	Security	Shares	Price	Value
Grant/Award	Phantom Stock Units SSP ^{F1, F2}	24	$25.01	$600.24

Holdings After Transaction: Phantom Stock Units SSP — 786,154 contracts (Direct)

Holdings Before and After: Phantom Stock Units SSP, 786,130 to 786,154 contracts (Direct)

Footnotes (2)

F1. Each unit represents one phantom share of common stock.
F2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Key Figures

Phantom units granted: 24.0000 units Reference price per unit: $25.0100 Total phantom units after grant: 786154.0000 units

3 metrics

Phantom units granted 24.0000 units Phantom Stock Units SSP granted to Albert Bourla on 2026-07-31

Reference price per unit $25.0100 Per-unit price reported for the July 31, 2026 phantom unit grant

Total phantom units after grant 786154.0000 units Total Phantom Stock Units SSP directly owned following the transaction

Key Terms

Phantom Stock Units SSP, Nonfunded Deferred Compensation and Supplemental Savings Plan, separation from service

3 terms

Phantom Stock Units SSP financial

"security_title: "Phantom Stock Units SSP""

Nonfunded Deferred Compensation and Supplemental Savings Plan financial

"acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan"

separation from service financial

"are settled in cash following the reporting person's separation from service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pfizer (PFE) report for Albert Bourla on this Form 4?

Albert Bourla received a grant of 24.0000 Phantom Stock Units SSP tied to Pfizer common stock. These units are part of a deferred compensation arrangement and are reported as derivative securities acquired on July 31, 2026.

What are the key terms of the Phantom Stock Units reported by Pfizer (PFE)?

Each Phantom Stock Unit represents one phantom share of Pfizer common stock and is settled in cash. The units were acquired under Pfizer’s Nonfunded Deferred Compensation and Supplemental Savings Plan and may be moved into an alternative investment account at any time.

How many phantom stock units does Albert Bourla hold after this Pfizer (PFE) Form 4 transaction?

After the reported grant, Albert Bourla holds a total of 786154.0000 Phantom Stock Units SSP. This total reflects all such units reported as directly owned following the July 31, 2026 award of 24.0000 additional units.

Was the Pfizer (PFE) Form 4 transaction for Albert Bourla a purchase or a grant?

The transaction is reported as a grant/award acquisition of Phantom Stock Units, coded “A” for acquisition. It represents compensation awarded under a deferred compensation plan, not an open-market stock purchase or sale.

How is the value of Albert Bourla’s Pfizer (PFE) Phantom Stock Units measured in this Form 4?

The reported reference price for the grant is $25.0100 per unit. Each unit corresponds to one phantom share of common stock, and the units are ultimately settled in cash following Bourla’s separation from service from Pfizer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOURLA ALBERT

(Last)

(First)

(Middle)

66 HUDSON BOULEVARD EAST

ATTN: CORPORATE SECRETARY

(Street)

NEW YORK

10001-2192

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Phantom Stock Units SSP	⁽¹⁾	07/31/2026		A		24		⁽²⁾	⁽²⁾	Common Stock	24	$25.01	786,154	D

Explanation of Responses:

1. Each unit represents one phantom share of common stock.

2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

	/s/ Shanice A. Reid, by power of atty., for Albert Bourla	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR